Search clinical trials for: rFVIIa

Total 197 results

IRCCS Policlinico S. Matteo

Completed

Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH) (PRE-SICH)

Intracerebral Hemorrhage

Italy
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Janssen Research & Development, LLC

Completed

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Healthy

Netherlands
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Acquired Hemophilia A

United States
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
CSL Behring

Completed

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Australia, Austria, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Novo Nordisk A/S

Completed

Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Joseph Broderick, MD
Novo Nordisk A/S; National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (FASTEST)

Intracerebral Hemorrhage

United States, Canada, Germany, Japan, Spain, United Kingdom
Centre Hospitalier Universitaire de Nīmes
Assistance Publique - Hôpitaux de Paris; University Hospital, Geneva; University... and other collaborators

Completed

rhuFVIIa in Post-partum Hemorrhage

Postpartum Hemorrhage

France, Switzerland
Bayer

Completed

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (Leopold II)

Hemophilia A

China, United States, Ukraine, Taiwan, Mexico, Thailand, Romania, Colombia, Turkey, Serbia, Russian Federation, South Africa, Japan, Indonesia, Argentina, Czech Republic, India, Slovakia
Bayer

Terminated

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, Canada, Switzerland, Estonia, Taiwan, France, Chile, Netherlands, United Kingdom, Austria, New Zealand, South Africa, Romania, Croatia, Israel, Germany, Poland, Australia, Denmark, Turkey, Argentina, Lithuan... and more
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Bulgaria, Ukraine, Czechia, United States, Georgia, South Africa
Erasme University Hospital
Fractyl Laboratories, Inc.

Completed

Effect of DMR in the Treatment of NASH (DMR_NASH_001)

NASH - Nonalcoholic Steatohepatitis

Belgium
Academisch Medisch Centrum - Universiteit van Amsterdam...
Fractyl Health, Inc.

Not yet recruiting

Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients (REMIND)

Diabetes Mellitus, Type 2
Gaia AG
Hannover Medical School; Universitätsklinikum Schleswig-Holstein, Campus Kiel

Active, not recruiting

Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout (LAVENDER)

Stress | Burnout

Germany
Leiden University Medical Center
Novo Nordisk A/S; University of Oxford; Herlev Hospital; VU University of Amsterdam

Completed

NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL

Post Partum Hemorrhage

Netherlands
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
StimLabs

Unknown

Efficacy of Human Placental Graft in Diabetic Foot Ulcers

Diabetic Foot

United States
Dr. David Gladstone
Canadian Institutes of Health Research (CIHR)

Completed

"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT)

Stroke

Canada
KU Leuven

Recruiting

Effect of an Interdisciplinary Spine Rehabilitation Program (PROGRESS)

Low Back Pain | Spine Disease

Belgium
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
CSL Behring

Completed

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Healthy

Germany
Takeda
Takeda Pharma Korea Co. Ltd.

Completed

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Hemophilia A

Korea, Republic of
Craig Seaman

Terminated

Weight-based Dosing in Hemophilia A

Hemophilia

United States
Oslo University Hospital

Completed

A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor (BPATXAS)

Hereditary Factor VIII Deficiency Disease With Inhibitor

Norway
Emory University
Takeda Pharmaceuticals North America, Inc.

Recruiting

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (SAFE)

Hemophilia A

United States
Fractyl Health Inc.

Completed

Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Diabetes Mellitus, Type 2 | Noninsulin-Dependent Diabetes Mellitus

United Kingdom, Belgium, Brazil, Italy, Netherlands
Bayer

Completed

Russian Kogenate Pediatric Study

Hemophilia A

Russian Federation
University Of Perugia

Unknown

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

Intracerebral Hemorrhage

Italy
Skane University Hospital
CSL Behring; Versiti

Completed

The Von Willebrand Disease (VWD) International Prophylaxis Study (VIP)

Von Willebrand Disease

United States, Sweden
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Octapharma

Completed

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (WONDERS)

Prevent Bleeding in Major Surgery

United States, Turkey, Romania, India, Bulgaria, Italy, Oman, Poland, South Africa
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Octapharma

Completed

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Severe Hemophilia A

United States, Bulgaria
University of Utah
Sheila B. Terry Memorial Research Fund

Terminated

Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage

Intracranial Hemorrhage
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

Austria, United Kingdom, Bulgaria, Hungary, Germany, Poland, Romania, Slovakia
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States
Octapharma

Completed

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

France, Japan, United States, Canada, Croatia, Finland, Netherlands, North Macedonia, Slovenia
Wayne State University
Genentech, Inc.

Recruiting

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis (STEP)

Hemophilia A

United States
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
Turkish Society of Hematology

Unknown

Turkish Acquired Haemophilia Registry (EHEM)

Acquired Haemophilia

Turkey
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Children's Hospital Los Angeles
Grifols Biologicals, LLC

Active, not recruiting

Preventing Inhibitor Recurrence Indefinitely (PRIORITY)

Hemophilia A | Immune Tolerance

United States
Federico II University

Completed

Intensive Replacement Treatment in Haemophilia Patients With Synovitis

Hemophilia A

Italy

Search clinical trials for: rFVIIa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations